S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
House GOP seeks new restrictions on use of US oil stockpile
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
House GOP seeks new restrictions on use of US oil stockpile
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
House GOP seeks new restrictions on use of US oil stockpile
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
House GOP seeks new restrictions on use of US oil stockpile
NASDAQ:GOSS

Gossamer Bio - GOSS Stock Forecast, Price & News

$2.43
+0.11 (+4.74%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.29
▼
$2.53
50-Day Range
$1.74
▼
$9.39
52-Week Range
$1.57
▼
$15.19
Volume
2.81 million shs
Average Volume
3.49 million shs
Market Capitalization
$229.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.25

Gossamer Bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
321.8% Upside
$10.25 Price Target
Short Interest
Bearish
38.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
1.18mentions of Gossamer Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.75) to ($2.42) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

238th out of 1,055 stocks

Pharmaceutical Preparations Industry

109th out of 519 stocks

See Top Rated MarketRank™ Stocks Here

GOSS stock logo

About Gossamer Bio (NASDAQ:GOSS) Stock

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.

Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

GOSS Stock News Headlines

January 20, 2023 | americanbankingnews.com
Analysts Set Gossamer Bio, Inc. (NASDAQ:GOSS) PT at $9.64
January 4, 2023 | finance.yahoo.com
Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?
January 28, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
January 4, 2023 | finance.yahoo.com
Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
January 3, 2023 | msn.com
Looking Into Gossamer Bio's Recent Short Interest
December 27, 2022 | msn.com
180 Life Sciences, KalVista top healthcare gainers; Edesa, Nutex among losers
December 26, 2022 | finance.yahoo.com
Bullish insiders at Gossamer Bio, Inc. (NASDAQ:GOSS) loaded up on US$1.2m of stock earlier this year
December 8, 2022 | seekingalpha.com
Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise
January 28, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
December 7, 2022 | marketwatch.com
Gossamer Bio: Seralutinib Meets Primary Endpoint in Phase 2 Trial in PAH
December 7, 2022 | seekingalpha.com
Gossamer Bio downgraded to Equal Weight at Barclays after PAH readout
December 7, 2022 | msn.com
Barclays Downgrades Gossamer Bio: Here's What You Need To Know
December 7, 2022 | markets.businessinsider.com
What 9 Analyst Ratings Have To Say About Gossamer Bio
December 7, 2022 | msn.com
Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug
December 7, 2022 | proactiveinvestors.com
Gossamer Bio tumbles as hypertension drug underperforms rival product in Phase 2 trial
December 6, 2022 | seekingalpha.com
Gossamer sheds 63% even as PAH candidate reaches main goal in Phase 2 trial
December 6, 2022 | seekingalpha.com
Gossamer Bio selloff is an overreaction - Piper Sandler
December 6, 2022 | finance.yahoo.com
Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH
November 25, 2022 | finance.yahoo.com
Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial
November 17, 2022 | markets.businessinsider.com
4 Analysts Have This to Say About Gossamer Bio
November 8, 2022 | msn.com
What Makes Gossamer Bio (GOSS) a New Buy Stock
November 3, 2022 | finance.yahoo.com
Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update
October 24, 2022 | finance.yahoo.com
Goldman Sachs Says These 2 Buy-Rated Stocks Have at Least 60% Upside Potential
October 20, 2022 | forbes.com
Gossamer Bio
October 20, 2022 | cnbc.com
Goldman says buy this under-the-radar biopharma stock expected to rally nearly 80%
October 20, 2022 | markets.businessinsider.com
What 5 Analyst Ratings Have To Say About Gossamer Bio
October 18, 2022 | finance.yahoo.com
Gossamer Bio, Inc. (GOSS)
See More Headlines
Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

GOSS Company Calendar

Last Earnings
11/03/2022
Today
1/28/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GOSS
CUSIP
N/A
CIK
1728117
Web
www.gossamerbio.com
Phone
(858) 684-1300
Fax
N/A
Employees
185
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.25
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+321.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.89)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-234,000,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-480.17%
Return on Assets
-76.14%

Debt

Debt-to-Equity Ratio
3.73
Current Ratio
5.93
Quick Ratio
5.93

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.59 per share
Price / Book
1.53

Miscellaneous

Outstanding Shares
94,480,000
Free Float
86,635,000
Market Cap
$229.59 million
Optionable
Not Optionable
Beta
1.12

Key Executives

  • Faheem Hasnain
    Chairman, President & Chief Executive Officer
  • Bryan GiraudoBryan Giraudo
    Chief Operating & Financial Officer
  • Richard Aranda
    Chief Medical Officer
  • Laura CarterLaura Carter
    Chief Scientific Officer
  • Christian Waage
    Secretary, General Counsel & Executive VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













GOSS Stock - Frequently Asked Questions

Should I buy or sell Gossamer Bio stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GOSS shares.
View GOSS analyst ratings or view top-rated stocks.

What is Gossamer Bio's stock price forecast for 2023?

10 analysts have issued 1 year price objectives for Gossamer Bio's stock. Their GOSS share price forecasts range from $2.00 to $24.00. On average, they anticipate the company's share price to reach $10.25 in the next year. This suggests a possible upside of 321.8% from the stock's current price.
View analysts price targets for GOSS or view top-rated stocks among Wall Street analysts.

How have GOSS shares performed in 2023?

Gossamer Bio's stock was trading at $2.17 on January 1st, 2023. Since then, GOSS shares have increased by 12.0% and is now trading at $2.43.
View the best growth stocks for 2023 here.

When is Gossamer Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our GOSS earnings forecast.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) released its earnings results on Thursday, November, 3rd. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.01.

What other stocks do shareholders of Gossamer Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Stoke Therapeutics (STOK), Precision BioSciences (DTIL) and Invitae (NVTA).

When did Gossamer Bio IPO?

(GOSS) raised $230 million in an initial public offering on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

What is Gossamer Bio's stock symbol?

Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Sequoia Financial Advisors LLC (0.03%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Luisa Salter-Cid, Richard Aranda and Waage Christian.
View institutional ownership trends.

How do I buy shares of Gossamer Bio?

Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gossamer Bio's stock price today?

One share of GOSS stock can currently be purchased for approximately $2.43.

How much money does Gossamer Bio make?

Gossamer Bio (NASDAQ:GOSS) has a market capitalization of $229.59 million. The company earns $-234,000,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis.

How many employees does Gossamer Bio have?

The company employs 185 workers across the globe.

How can I contact Gossamer Bio?

Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The official website for the company is www.gossamerbio.com. The company can be reached via phone at (858) 684-1300 or via email at ir@gossamerbio.com.

This page (NASDAQ:GOSS) was last updated on 1/28/2023 by MarketBeat.com Staff